Combination drug therapy for EGFR lung cancer that turned into small cell
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new targeted drug (limertinib) plus chemotherapy (carboplatin and etoposide) for people whose EGFR-mutant lung cancer has changed into small cell lung cancer (SCLC) after prior targeted therapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with non-small cell lung cancer (NSCLC) that has an EGFR mutation (like exon 19 deletion or L858R).
- You have already been treated with a targeted EGFR drug (like gefitinib, erlotinib, osimertinib, etc.) and your cancer got worse. A biopsy then confirmed it changed into small cell lung cancer (SCLC).
- You are between 18 and 80 years old.
- You are in fairly good health (able to do daily activities with little or no help).
- You have at least one tumor that can be measured on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (a third-generation EGFR-TKI and anlotinib) as maintenance therapy for people with non-small cell lung cancer that has changed into small cell cancer after resistance to EGFR-TKI therapy. It may help control the cancer longer.
This trial tests a new study drug (PF08634404) combined with standard chemotherapy for people whose non-small cell lung cancer has changed into a more aggressive form called small cell lung cancer. It hopes to improve outcomes by targeting the cancer in two ways.
This trial tests a combination of two targeted drugs (DZD9008 and AZD4205) for people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests a combination of two targeted drugs (Glumetinib and Osimertinib) against standard chemotherapy for people with non-small cell lung cancer that has stopped responding to initial targeted therapy. It may be an option if your tumor has a specific genetic change called MET amplification or overexpression.
This trial tests a new targeted pill (befotertinib) given before surgery, either with another targeted drug (bevacizumab) or with standard chemotherapy. The goal is to shrink the tumor and improve outcomes for people with a specific type of lung cancer.
This trial tests a new drug (tarlatamab) combined with chemotherapy and immunotherapy for people whose lung cancer has changed from one type (adenocarcinoma) to small cell lung cancer after treatment with EGFR targeted therapy. The goal is to see if this combination is safe and works well.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.